Business Description
Square Pharmaceuticals PLC
ISIN : BD0473SQPH00
Description
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. The company is also involved in the marketing of pesticide products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 26.27 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.08 | |||||
| Interest Coverage | 221.11 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 16.81 | |||||
| Beneish M-Score | -1.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.4 | |||||
| 3-Year EBITDA Growth Rate | 8.5 | |||||
| 3-Year EPS without NRI Growth Rate | 12.9 | |||||
| 3-Year FCF Growth Rate | -13.5 | |||||
| 3-Year Book Growth Rate | 15.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.01 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.16 | |||||
| 9-Day RSI | 37.46 | |||||
| 14-Day RSI | 41.67 | |||||
| 6-1 Month Momentum % | 0.67 | |||||
| 12-1 Month Momentum % | 0.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.37 | |||||
| Quick Ratio | 10.29 | |||||
| Cash Ratio | 9.25 | |||||
| Days Inventory | 105.96 | |||||
| Days Sales Outstanding | 14.82 | |||||
| Days Payable | 11.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.77 | |||||
| Dividend Payout Ratio | 0.47 | |||||
| 3-Year Dividend Growth Rate | 23.3 | |||||
| Forward Dividend Yield % | 4.77 | |||||
| 5-Year Yield-on-Cost % | 10.28 | |||||
| Shareholder Yield % | 4.2 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.72 | |||||
| Operating Margin % | 27.92 | |||||
| Net Margin % | 30.64 | |||||
| ROE % | 18.05 | |||||
| ROA % | 16.6 | |||||
| ROIC % | 22.19 | |||||
| ROC (Joel Greenblatt) % | 60.34 | |||||
| ROCE % | 20.32 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.86 | |||||
| Forward PE Ratio | 8.64 | |||||
| PE Ratio without NRI | 9.86 | |||||
| Shiller PE Ratio | 13.39 | |||||
| Price-to-Owner-Earnings | 10.51 | |||||
| PEG Ratio | 0.82 | |||||
| PS Ratio | 3 | |||||
| PB Ratio | 1.7 | |||||
| Price-to-Tangible-Book | 1.7 | |||||
| Price-to-Free-Cash-Flow | 38.68 | |||||
| Price-to-Operating-Cash-Flow | 22.88 | |||||
| EV-to-EBIT | 6.27 | |||||
| EV-to-Forward-EBIT | 5.69 | |||||
| EV-to-EBITDA | 5.96 | |||||
| EV-to-Forward-EBITDA | 5.6 | |||||
| EV-to-Revenue | 2.22 | |||||
| EV-to-Forward-Revenue | 1.91 | |||||
| EV-to-FCF | 28.71 | |||||
| Price-to-Projected-FCF | 1.13 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.85 | |||||
| Price-to-Graham-Number | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 3.15 | |||||
| Price-to-Net-Cash | 4.41 | |||||
| Earnings Yield (Greenblatt) % | 15.96 | |||||
| Forward Rate of Return (Yacktman) % | 14.68 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Square Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil BDT) | 62,019.772 | ||
| EPS (TTM) (BDT) | 21.29 | ||
| Beta | 0 | ||
| Volatility % | 4.85 | ||
| 14-Day RSI | 41.67 | ||
| 14-Day ATR (BDT) | 0.699431 | ||
| 20-Day SMA (BDT) | 210.31 | ||
| 12-1 Month Momentum % | 0.67 | ||
| 52-Week Range (BDT) | 209.8 - 214.1 | ||
| Shares Outstanding (Mil) | 886.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Square Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Square Pharmaceuticals PLC Stock Events
| Event | Date | Price(BDT) | ||
|---|---|---|---|---|
| No Event Data | ||||
Square Pharmaceuticals PLC Frequently Asked Questions
What is Square Pharmaceuticals PLC(DHA:SQURPHARMA)'s stock price today?
The current price of DHA:SQURPHARMA is BDT209.80. The 52 week high of DHA:SQURPHARMA is BDT214.10 and 52 week low is BDT209.80.
When is next earnings date of Square Pharmaceuticals PLC(DHA:SQURPHARMA)?
The next earnings date of Square Pharmaceuticals PLC(DHA:SQURPHARMA) is .
Does Square Pharmaceuticals PLC(DHA:SQURPHARMA) pay dividends? If so, how much?
The Dividend Yield %  of Square Pharmaceuticals PLC(DHA:SQURPHARMA) is 4.77% (As of Today), Highest Dividend Payout Ratio of Square Pharmaceuticals PLC(DHA:SQURPHARMA) was 0.47. The lowest was 0.19. And the median was 0.23. The  Forward Dividend Yield % of Square Pharmaceuticals PLC(DHA:SQURPHARMA) is 4.77%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers